ELOXX PHARMACEUTICALS INC

ELOXNASDAQ

🏆 #4036 by market capUS Equity

$19.18▲ $2.46 (+12.82%)

Live

1h—

24h▲ 12.8%

7d—

14d—

30d—

1y—

🏦Market Cap

$77M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

4.7x

Fair

Otter Score

Fair

No chart data available for ELOX.

Trading Snapshot

Day Range: $18.94 – $19.34
52-Week Range: $0.00 – $19.36
Volume: $2.80B
Avg Volume: $2.73B
Shares Outstanding: 4.0M
Next Earnings: Oct 17, 2026

Fundamentals Snapshot

Annual Revenue: $151,870
Last Q Revenue: $39,326
P/E Ratio: —
P/S Ratio: 4.7x
EPS (TTM): $-7.06
Dividend Yield: —

Why Investors Own ELOX

✓High-growth profile — revenue up +42.7% YoY with expanding US Equity exposure.
✓Healthy economics — 37% gross margin and 24% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$151,870▲ +49.5% YoY

Gross Margin (TTM)

37.4%▲ +4.5% YoY

Operating Income (TTM)

$23,844▲ +49.5% YoY

Free Cash Flow (TTM)

$37,056▲ +49.5% YoY

About ELOXX PHARMACEUTICALS INC

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.

🦦